Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
1. ARVN released first-in-human data for Parkinson’s treatment ARV-102. 2. ARV-102 shows substantial reduction of LRRK2 protein and favorable safety profile. 3. Ongoing Phase 1 trial includes both SAD and MAD cohorts for ARV-102. 4. Encouraging pharmacodynamic outcomes noted, but ARVN stock is currently down 4.93%.